Reliability of the modified Hammersmith functional motor scale in young children with spinal muscular atrophy

Muscle and Nerve

Volumn 44, Issue 2, 2011, Pages 246-251

  Krosschell, Kristin J ^a   Scott, Charles B ^b   Maczulski, Jo Anne ^c   Lewelt, Aga J ^d   Reyna, Sandra P ^d   Swoboda, Kathryn J ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CBS   (United States)

^c Pediatric Occupational Therapy Services   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

MHFMS; Modified hammersmith functional motor scale; Outcome; Spinal muscular atrophy; Test retest reliability

Indexed keywords

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE COURSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFANT; MALE; MODIFIED HAMMERSMITH FUNCTIONAL MOTOR SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SPINAL MUSCULAR ATROPHY; TEST RETEST RELIABILITY;

CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MOTOR SKILLS; REPRODUCIBILITY OF RESULTS; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD;

EID: 79960553384     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22040     Document Type: Article

References (37)

1. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000;15:228-237.
2. Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 1996;3:97-110.
3. Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Angou G, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol 2007;22:957-966.
4. Moxley RT III. Functional testing. Muscle Nerve 1990;13(suppl): S26-S29.
5. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith Functional Motor Scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 2003;7:155-159.
6. Nelson L, Owens H, Hynan LS, Iannaccone ST. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord 2006;16:374-380.
7. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith Functional Motor Scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006; 16:417-426.
8. O'Hagen JM, Glanzman AM, McDermott MP, Ryan GP, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 2007;17:693-697.
9. Iannaccone ST, Hynan LS. Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 2003;60:1130-1136.
10. Mercuri E, Mayhew A, Muntoni F, Messina S, Strab V, Van Ommen GJ, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ ENMC workshop on outcome measures, 12th-13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June-1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 2008;18:894-903.
11. Mercuri E, Messina S, Battini R, Beradinelli A, Boffi P, Bono R, et al. Reliability of the Hammersmith Functional Motor Scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord 2006; 16:93-98.
12. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride M, Prior TW, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005;57:704-712.
13. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE 2009;4:e5268.
14. Mercuri E, Bertini E, Messina S, Pellicioni M, D'Amico A, Colitto F, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004;14:130-135.
15. Pane M, Staccioli S, Messina S, D'Amico A, Pellicioni M, Mazzone ES, et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008;18:536-540.
16. Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, et al. SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE 2010;5.
17. Bertini E, Burghes A, Bushby K, Estournet-Mathiaud B, Finkel RS, Hughes RA, et al. 134th ENMC International Workshop: Outcome measures and treatment of spinal muscular atrophy, 11-13 February 2005, Naarden, The Netherlands. Neuromuscul Disord 2005;15: 802-816.
18. Bono R, Inverno M, Botteon G, Iotti E, Estenniene M, Bernardinelli A, et al. Prospective study of gross motor development in children with SMA type II. Ital J Neurol Sci 1995;16:223-230.
19. Iannaccone ST, Russman BS, Browne RH, Buncher CR, White M, Samaha FJ. Prospective analysis of strength in spinal muscular atrophy. J Child Neurol 2000;15:97-101.
20. Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 2001;45:174-181.
21. Russman BS, Buncher CR, White M, Samaha FJ, Iannaccone ST. Function changes in spinal muscular atrophy II and III. The DCN/ SMA Group. Neurology 1996;47:973-976.
22. Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 1997;146:67-72.
23. Crawford TO. From enigmatic to problematic: the new molecular genetics of childhood spinal muscular atrophy. Neurology 1996;46: 335-340.
24. Crawford TO. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 2004;14:456-460.
25. Dubowitz V. Infantile muscular atrophy. A prospective study with particular reference to a slowly progressive variety. Brain 1964;87: 707-718.
26. Mercuri E, Mazzone E. Choosing the right clinical outcome measure: from the patient to the statistician and back. Neuromuscul Disord 2011;21:16-19.
27. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-428.
28. Kuo YL, Liao HF, Chen PC, Hsieh WS, Hwang AW. The influence of wakeful prone positioning on motor development during the early life. J Dev Behav Pediatr 2008;29:367-376.
29. Liao PJ, Zawacki L, Campbell SK. Annotated bibliography: effects of sleep position and play position on motor development in early infancy. Phys Occup Ther Pediatr 2005;25:149-160.
30. Piper M, Darrah J. Motor assessment of the developing infant. Philadelphia: W.B. Saunders; 1994.
31. Bayley N. Bayley Scales of Infant and Toddler Development (BSIDIII): Motor scale administration and technical manual, 3rd ed. San Antonio, Texas: Psychological Corporation; 2005.
32. Folio M, Fewell R. Peabody developmental motor scales, 2nd ed. Austin, Texas: PRO-ED; 2000.
33. Cintas H. Cross-cultural similarities and differences in development and the impact of parental expectations on motor behavior. Pediatr Phys Ther 1995;7:103-111.
34. Nelson EA, Yu LM, Wong D, Wong HY, Yim L. Rolling over in infants: age, ethnicity, and cultural differences. Dev Med Child Neurol 2004;46:706-709.
35. Crowe TK, McClain C, Provost B. Motor development of Native American children on the Peabody Developmental Motor Scales. Am J Occup Ther 1999;53:514-518.
36. Malina RM. Racial/ethnic variation in the motor development and performance of American children. Can J Sport Sci 1988;13:136-143.
37. Ivanans T. Effect of maternal education and ethnic background on infant development. Arch Dis Child 1975;50:454-457.